F&V Capital Management’s Gilead Sciences GILD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $864K | Hold |
6,200
| – | – | 0.18% | 42 |
|
|
2025
Q4 | $761K | Hold |
6,200
| – | – | 0.16% | 42 |
|
|
2025
Q3 | $688K | Hold |
6,200
| – | – | 0.15% | 39 |
|
|
2025
Q2 | $687K | Sell |
6,200
-147,040
| -96% | -$15.6M | 0.18% | 38 |
|
|
2025
Q1 | $17.2M | Sell |
153,240
-2,090
| -1% | -$216K | 4.46% | 5 |
|
|
2024
Q4 | $14.3M | Sell |
155,330
-640
| -0.4% | -$57.6K | 3.78% | 11 |
|
|
2024
Q3 | $13.1M | Buy |
155,970
+9,760
| +7% | +$745K | 3.36% | 14 |
|
|
2024
Q2 | $10M | Buy |
146,210
+4,755
| +3% | +$317K | 2.92% | 16 |
|
|
2024
Q1 | $10.4M | Buy |
141,455
+2,260
| +2% | +$174K | 3.05% | 14 |
|
|
2023
Q4 | $11.3M | Buy |
139,195
+3,580
| +3% | +$279K | 3.62% | 10 |
|
|
2023
Q3 | $10.2M | Sell |
135,615
-1,845
| -1% | -$142K | 3.48% | 9 |
|
|
2023
Q2 | $10.6M | Sell |
137,460
-340
| -0.2% | -$27.1K | 3.42% | 11 |
|
|
2023
Q1 | $11.4M | Buy |
137,800
+6,360
| +5% | +$527K | 3.79% | 10 |
|
|
2022
Q4 | $11.3M | Sell |
131,440
-1,850
| -1% | -$147K | 3.76% | 10 |
|
|
2022
Q3 | $8.22M | Buy |
133,290
+455
| +0.3% | +$28.7K | 3.17% | 15 |
|
|
2022
Q2 | $8.21M | Buy |
132,835
+5,305
| +4% | +$328K | 2.92% | 19 |
|
|
2022
Q1 | $7.58M | Buy |
127,530
+4,860
| +4% | +$311K | 2.3% | 25 |
|
|
2021
Q4 | $8.91M | Buy |
122,670
+16,270
| +15% | +$1.12M | 2.99% | 18 |
|
|
2021
Q3 | $7.43M | Sell |
106,400
-5,080
| -5% | -$357K | 2.98% | 20 |
|
|
2021
Q2 | $7.68M | Buy |
111,480
+5,430
| +5% | +$363K | 2.82% | 21 |
|
|
2021
Q1 | $6.85M | Buy |
106,050
+15,910
| +18% | +$1.03M | 2.56% | 22 |
|
|
2020
Q4 | $5.25M | Sell |
90,140
-9,545
| -10% | -$576K | 2.27% | 24 |
|
|
2020
Q3 | $6.3M | Buy |
99,685
+615
| +0.6% | +$42.6K | 3.06% | 14 |
|
|
2020
Q2 | $7.62M | Buy |
99,070
+3,450
| +4% | +$264K | 3.86% | 6 |
|
|
2020
Q1 | $7.15M | Buy |
95,620
+21,560
| +29% | +$1.49M | 4.55% | 4 |
|
|
2019
Q4 | $4.81M | Sell |
74,060
-165
| -0.2% | -$10.7K | 2.61% | 19 |
|
|
2019
Q3 | $4.7M | Sell |
74,225
-600
| -0.8% | -$39.2K | 2.92% | 19 |
|
|
2019
Q2 | $5.05M | Sell |
74,825
-1,435
| -2% | -$94.4K | 3.01% | 20 |
|
|
2019
Q1 | $4.96M | Sell |
76,260
-4,110
| -5% | -$273K | 2.83% | 19 |
|
|
2018
Q4 | $5.03M | Buy |
80,370
+2,430
| +3% | +$170K | 3.04% | 16 |
|
|
2018
Q3 | $6.02M | Buy |
77,940
+1,275
| +2% | +$96.3K | 3.24% | 16 |
|
|
2018
Q2 | $5.43M | Sell |
76,665
-1,927
| -2% | -$136K | 3.12% | 16 |
|
|
2018
Q1 | $5.92M | Buy |
78,592
+242
| +0.3% | +$19.2K | 3.23% | 12 |
|
|
2017
Q4 | $5.61M | Buy |
78,350
+1,370
| +2% | +$104K | 2.92% | 13 |
|
|
2017
Q3 | $6.24M | Sell |
76,980
-2,590
| -3% | -$198K | 3.65% | 10 |
|
|
2017
Q2 | $5.63M | Buy |
79,570
+120
| +0.2% | +$7.99K | 3.2% | 12 |
|
|
2017
Q1 | $5.4M | Buy |
79,450
+2,425
| +3% | +$171K | 3.14% | 14 |
|
|
2016
Q4 | $5.52M | Sell |
77,025
-1,385
| -2% | -$103K | 3.47% | 10 |
|
|
2016
Q3 | $6.2M | Buy |
78,410
+2,775
| +4% | +$225K | 4.29% | 8 |
|
|
2016
Q2 | $6.31M | Buy |
75,635
+14,405
| +24% | +$1.28M | 4.7% | 5 |
|
|
2016
Q1 | $5.62M | Sell |
61,230
-710
| -1% | -$64K | 4.43% | 8 |
|
|
2015
Q4 | $6.27M | Buy |
61,940
+745
| +1% | +$77.5K | 4.57% | 5 |
|
|
2015
Q3 | $6.01M | Buy |
61,195
+21,470
| +54% | +$2.38M | 4.27% | 4 |
|
|
2015
Q2 | $4.65M | Sell |
39,725
-820
| -2% | -$89.6K | 3.16% | 12 |
|
|
2015
Q1 | $3.98M | Buy |
+40,545
| New | +$4.12M | 2.71% | 18 |
|
Other funds holding GILD
VCM
VPM
F&V Capital Management's GILD Position: Q1 2026 in Review
F&V Capital Management held its Gilead Sciences (GILD) position steady in Q1 2026 at 6,200 shares worth $864K. The position accounts for 0.18% of the portfolio, ranked #42.
F&V Capital Management first reported a position in GILD in Q1 2015 and has held it in 45 quarters since. The position peaked at $17.2M in Q1 2025. 2,309 funds tracked by Wall St. Rank hold GILD as of Q1 2026.
- F&V Capital Management held 6,200 shares of Gilead Sciences worth $864K as of Q1 2026.
- F&V Capital Management left its Gilead Sciences share count unchanged in Q1 2026.
- Gilead Sciences made up 0.18% of F&V Capital Management's portfolio in Q1 2026, its #42 holding.
- F&V Capital Management first reported a position in Gilead Sciences in Q1 2015 and has held it in 45 quarters since.
- F&V Capital Management's Gilead Sciences position peaked at $17.2M in Q1 2025.
- 2,309 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.
Based on F&V Capital Management's 13F filing for Q1 2026, filed 27 Apr 2026.